Back to Browse Journals » Drug Design, Development and Therapy » Volume 5

Bioequivalence of oxymorphone extended release and crush-resistant oxymorphone extended release

Authors Benedek IH, Jobes J, Xiang Q, Fiske WD

Published Date October 2011 Volume 2011:5 Pages 455—463

DOI http://dx.doi.org/10.2147/DDDT.S24372

Published 31 October 2011

Irma H Benedek, Janet Jobes, Qinfang Xiang, William D Fiske
Endo Pharmaceuticals Inc, Chadds Ford, PA, USA

Background: A formulation of crush-resistant extended-release opioids may deter abuse. The purpose of this study was to evaluate the bioequivalence of oxymorphone extended-release (Oxy-ER) and a crush-resistant formulation of oxymorphone extended-release (Oxy-CRF).
Methods: In three open-label, randomized studies, healthy adults at a clinical research center received two single oral doses of Oxy-ER and two single doses of Oxy-CRF, each separated by a ≥7-day washout. Doses were administered under fasted conditions (study 1, 5 mg doses; study 2, 40 mg doses) or after a high-fat breakfast (study 3, 40 mg doses). Subjects administered 40 mg doses also received naltrexone. The primary endpoint was systemic oxymorphone exposure; the bioequivalence criterion was met if the 90% confidence intervals of the geometric mean ratio (Oxy-CRF/Oxy-ER) for oxymorphone area under the curve from time 0 to the last measured concentration (AUC0–t), AUC from time 0 to infinity (AUC0–inf), and maximum plasma concentration (Cmax) were within 0.8–1.25. Safety was assessed by monitoring adverse events.
Results: In studies 1, 2, and 3, the safety population comprised 30, 37, and 36 subjects and the pharmacokinetics population comprised 27, 30, and 29 subjects, respectively. Oxy-ER and Oxy-CRF produced similar mean ± standard deviation oxymorphone AUC0–t (study 1, 5.05 ± 1.55 versus 5.29 ± 1.52 ng · h/mL; study 2, 31.51 ± 10.95 versus 31.23 ± 10.33 ng · h/mL; study 3, 50.16 ± 14.91 versus 49.01 ± 14.03 ng · h/mL) and Cmax (0.38 ± 0.11 versus 0.37 ± 0.12 ng/mL; 2.37 ± 1.20 versus 2.41 ± 0.94 ng/mL; 5.87 ± 1.99 versus 5.63 ± 2.26 ng/mL) under all conditions. The 90% confidence intervals for plasma oxymorphone AUC0–t, AUC0–inf, and Cmax fulfilled the bioequivalence criterion. Adverse event rates were similar with Oxy-ER and Oxy-CRF (study 1, 25% versus 23%; study 2, 9% versus 16%; study 3, 20% each group).
Conclusion: Oxy-CRF and Oxy-ER (5 mg and 40 mg) are bioequivalent under fasted and fed conditions, suggesting that Oxy-CRF will have clinical efficacy and safety equivalent to Oxy-ER.

Keywords: abuse deterrent, bioequivalence, opioid, oxymorphone, pharmacokinetics, substance abuse

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab

Ignacio Garcia-Valladares, Raquel Cuchacovich, Luis R Espinoza

Drug Design, Development and Therapy 2011, 5:41-49

Published Date: 10 January 2011

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Surface activity of surfactant spiked with vitamin A

Vadim Bronshtein, Vugranam Venkatesh, Jas Aulakh, Philippe Chessex

Drug Design, Development and Therapy 2008, 2:145-150

Published Date: 14 August 2008

Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection

Toshio Uraoka, Yutaka Saito, Kazuhide Yamamoto, Takahiro Fujii

Drug Design, Development and Therapy 2008, 2:131-138

Published Date: 11 August 2008

Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations

Akira Fujii, Norio Yasui-Furukori, Taku Nakagami, Takenori Niioka, Manabu Saito, et al

Drug Design, Development and Therapy 2008, 2:139-144

Published Date: 11 August 2008

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008

Aerosol delivery by an ultrasonic nebulizer during different mechanical ventilation settings in a lung model – a pilot study

Michael Winterhalter, Michael Bund, Nawid Khaladj, Christian Hagl, Andre Simon, et al

Drug Design, Development and Therapy 2008, 2:1-7

Published Date: 8 January 2008

Beyond post-marketing research and MedWatch: Long-term studies of drug risks

David B Resnik

Drug Design, Development and Therapy 2007, 1:1-5

Published Date: 4 October 2007